Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Accumulated Expenses (2020 - 2025)

Rapid Micro Biosystems' Accumulated Expenses history spans 6 years, with the latest figure at $6.6 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 6.11% year-over-year to $6.6 million; the TTM value through Sep 2025 reached $6.6 million, down 6.11%, while the annual FY2024 figure was $7.2 million, 27.15% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $6.6 million at Rapid Micro Biosystems, up from $5.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.9 million in Q4 2021 and bottomed at $595000.0 in Q1 2022.
  • The 5-year median for Accumulated Expenses is $7.0 million (2023), against an average of $6.2 million.
  • The largest annual shift saw Accumulated Expenses surged 1107.68% in 2022 before it decreased 28.59% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $10.9 million in 2021, then fell by 25.35% to $8.2 million in 2022, then grew by 21.56% to $9.9 million in 2023, then fell by 27.15% to $7.2 million in 2024, then fell by 8.44% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Accumulated Expenses are $6.6 million (Q3 2025), $5.7 million (Q2 2025), and $5.0 million (Q1 2025).